In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
about
New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.Melphalan-flufenamide is cytotoxic and potentiates treatment with chemotherapy and the Src inhibitor dasatinib in urothelial carcinoma.A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.In vitro and in vivo activity of melflufen (J1)in lymphomaPreclinical activity of melflufen (J1) in ovarian cancer.Future agents and treatment directions in multiple myeloma.Melphalan hydrochloride for the treatment of multiple myeloma.Nucleotide excision repair is a potential therapeutic target in multiple myeloma.Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma.A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cellsPreclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.Melflufen - a peptidase-potentiated alkylating agent in clinical trials.Design of Finasteride-Loaded Nanoparticles for Potential Treatment of Alopecia.
P2860
Q27004421-54ED0799-3DDE-48BD-A5B7-A1EF9F82EF56Q34501199-692BAB0B-F9BF-4AE8-8A1A-B8D1E28700D3Q34511534-443BAB66-8DD5-4230-ADE9-D1FD2068A6F7Q36642951-F1AF83A4-42CD-48F6-9EAD-8E14AF96F5EDQ36765319-E6C2FD97-4EF3-48E7-93BF-DEAD1920D59CQ37644866-FDD0F9D6-CF1A-4957-8C89-B79498A04499Q38172300-06DE00B6-169B-4135-AEAB-CB324B4EDF2DQ38704146-5B3D4F54-3D73-4E26-8D40-6EF20F2D00B8Q38739689-E6163148-DBDB-4B7A-9A1B-1718557A45CCQ38743857-01A127EE-4DB7-4077-B952-2E6D8D52954BQ39818766-8AF4D39A-FEE8-48EA-808E-673DD1846F95Q39836136-9A4763D6-BF22-420B-8F8E-BBBAD4287049Q41088379-B9CC3860-3681-473E-A94D-FC5C3F5E74A5Q42371678-1B45AC79-0F7D-458D-9EF5-DD75C35853C3Q50540368-05720E98-2CBC-42D8-90D0-6FC45A7CCEC6
P2860
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
In vitro and in vivo antitumor ...... gainst multiple myeloma cells.
@ast
In vitro and in vivo antitumor ...... gainst multiple myeloma cells.
@en
type
label
In vitro and in vivo antitumor ...... gainst multiple myeloma cells.
@ast
In vitro and in vivo antitumor ...... gainst multiple myeloma cells.
@en
prefLabel
In vitro and in vivo antitumor ...... gainst multiple myeloma cells.
@ast
In vitro and in vivo antitumor ...... gainst multiple myeloma cells.
@en
P2093
P2860
P1476
In vitro and in vivo antitumor ...... gainst multiple myeloma cells.
@en
P2093
Arghya Ray
Claudia Paba-Prada
Dharminder Chauhan
Jack Spira
Kristina Viktorsson
Nikhil Munshi
Rolf Lewensohn
P2860
P304
P356
10.1158/1078-0432.CCR-12-3752
P407
P577
2013-04-12T00:00:00Z